Jpmorgan Chase & CO Bicycle Therapeutics PLC Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 15,588 shares of BCYC stock, worth $308,798. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,588

Previous 10,106 54.25%

Holding current value

$308,798

Previous $182,000 113.19%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$16.75 - $26.1 $91,823 - $143,080	5,482 Added 54.25%	15,588 $388,000
Q4 2023 Feb 12, 2024	SELL	$13.29 - $22.2 $776,042 - $1.3 Million	-58,393 Reduced 85.25%	10,106 $182,000
Q3 2023 Nov 14, 2023	SELL	$19.9 - $26.25 $550,274 - $725,865	-27,652 Reduced 28.76%	68,499 $1.38 Million
Q2 2023 Aug 11, 2023	BUY	$18.95 - $28.67 $170,796 - $258,402	9,013 Added 10.34%	96,151 $2.45 Million
Q1 2023 May 11, 2023	BUY	$20.02 - $31.37 $78,718 - $123,346	3,932 Added 4.73%	87,138 $1.85 Million

Q4 2022 Feb 13, 2023	SELL	$20.37 - $32.9 $865,378 - $1.4 Million	-42,483 Reduced 33.8%	83,206 $2.46 Million
Q3 2022 Nov 14, 2022	BUY	$17.49 - $28.44 $738,620 - $1.2 Million	42,231 Added 50.6%	125,689 $2.92 Million
Q2 2022 Aug 11, 2022	BUY	$12.95 - $46.99 $952,537 - $3.46 Million	73,555 Added 742.75%	83,458 $1.4 Million
Q1 2022 May 11, 2022	BUY	$40.12 - $59.5 $283,849 - $420,962	7,075 Added 250.18%	9,903 $434,000
Q4 2021 Feb 10, 2022	BUY	$41.7 - $61.14 $61,007 - $89,447	1,463 Added 107.18%	2,828 $172,000
Q3 2021 Nov 12, 2021	BUY	$27.95 - $44.24 $38,151 - $60,387	1,365 New	1,365 $57,000

Others Institutions Holding BCYC

# of Institutions

Shares Held

30.6M

Call Options Held

85.5K

Put Options Held

11.6K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $588M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Bicycle Therapeutics PLC Transaction History